# Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis

> **NCT05260073** · — · COMPLETED · sponsor: **Almirall, S.A.** · enrollment: 300 (actual)

## Conditions studied

- Keratosis, Actinic

## Interventions

- **DRUG:** Tirbanibulin

## Key facts

- **NCT ID:** NCT05260073
- **Lead sponsor:** Almirall, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-09
- **Primary completion:** 2022-10-31
- **Final completion:** 2023-03-07
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2024-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05260073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05260073, "Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis". Retrieved via AI Analytics 2026-08-19 from https://api.ai-analytics.org/clinical/NCT05260073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*